Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David F Moreno

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Cancers|April 30, 2021
Defining an Ultra-Low Risk Group in Asymptomatic IgM Monoclonal GammopathyDavid F Moreno, Arturo Pereira, Natalia Tovar, et al.
British Journal of Haematology|October 9, 2022
Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemiaDavid F Moreno, Mónica López-Guerra, Sara Paz, et al.
Seminars in Hematology|May 17, 2025
Report of Consensus Panel 4 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with non-IgM lymphoplasmacytic lymphomaAlessandra Tedeschi, Rebecca Auer, Francesco Autore, et al.
Journal for Immunotherapy of Cancer|March 3, 2026
Enhanced antitumoral activity of the academic CAR-T ARI0002h against normal and low BCMA-expressing myeloma cells after incorporating a transmembrane CD28 domainOriol Cardus, Joan Mañé Pujol, Anna de Daniel, et al.
Oncoimmunology|July 13, 2025
TIGIT blockade in the context of BCMA-CART cell therapy does not augment efficacy in a multiple myeloma mouse modelAina Oliver-Caldes, Joan Mañe Pujol, Anthony M Battram, et al.
Leukemia & Lymphoma|March 27, 2020
Impact of intensifying primary antibiotic prophylaxis in at-home autologous stem cell transplantation program for lymphoma patientsLuis Gerardo Rodríguez-Lobato, Alexandra Martínez-Roca, David F Moreno, et al.
Annals of Hematology|May 11, 2026
Academic BCMA CAR-T (ARI0002h) achieves MRD-negative remission with sBCMA biomarker response in relapsed POEMS syndrome after double ASCTVíctor Torrecillas-Mayayo, Aina Oliver-Caldes, Nuria Martínez-Cibrian, et al.
Cancer Immunology Research|June 27, 2025
Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is LimitedLuis Gerardo Rodríguez-Lobato, Oriol Cardús, Joan Mañé-Pujol, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 15, 2025
Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation TrialsDavid F Moreno, Albert Oriol, Javier de la Rubia, et al.
Journal for Immunotherapy of Cancer|December 8, 2021
First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myelomaAina Oliver-Caldes, Raquel Jiménez, Marta Español-Rego, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Cancers|April 30, 2021
Defining an Ultra-Low Risk Group in Asymptomatic IgM Monoclonal GammopathyDavid F Moreno, Arturo Pereira, Natalia Tovar, et al.
British Journal of Haematology|October 9, 2022
Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemiaDavid F Moreno, Mónica López-Guerra, Sara Paz, et al.
Seminars in Hematology|May 17, 2025
Report of Consensus Panel 4 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with non-IgM lymphoplasmacytic lymphomaAlessandra Tedeschi, Rebecca Auer, Francesco Autore, et al.
Journal for Immunotherapy of Cancer|March 3, 2026
Enhanced antitumoral activity of the academic CAR-T ARI0002h against normal and low BCMA-expressing myeloma cells after incorporating a transmembrane CD28 domainOriol Cardus, Joan Mañé Pujol, Anna de Daniel, et al.
Oncoimmunology|July 13, 2025
TIGIT blockade in the context of BCMA-CART cell therapy does not augment efficacy in a multiple myeloma mouse modelAina Oliver-Caldes, Joan Mañe Pujol, Anthony M Battram, et al.
Leukemia & Lymphoma|March 27, 2020
Impact of intensifying primary antibiotic prophylaxis in at-home autologous stem cell transplantation program for lymphoma patientsLuis Gerardo Rodríguez-Lobato, Alexandra Martínez-Roca, David F Moreno, et al.
Annals of Hematology|May 11, 2026
Academic BCMA CAR-T (ARI0002h) achieves MRD-negative remission with sBCMA biomarker response in relapsed POEMS syndrome after double ASCTVíctor Torrecillas-Mayayo, Aina Oliver-Caldes, Nuria Martínez-Cibrian, et al.
Cancer Immunology Research|June 27, 2025
Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is LimitedLuis Gerardo Rodríguez-Lobato, Oriol Cardús, Joan Mañé-Pujol, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 15, 2025
Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation TrialsDavid F Moreno, Albert Oriol, Javier de la Rubia, et al.
Journal for Immunotherapy of Cancer|December 8, 2021
First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myelomaAina Oliver-Caldes, Raquel Jiménez, Marta Español-Rego, et al.
Pageof 6